Categories
BLOG

mmj sto

Matica Enterprises Inc. (MMJ.CN)

Previous Close 0.0250
Open 0.0000
Bid 0.0300 x 0
Ask 0.0350 x 0
Day’s Range 0.0000 – 0.0000
52 Week Range
Volume 0
Avg. Volume 228,375
Market Cap 9.558M
Beta (5Y Monthly) 1.51
PE Ratio (TTM) N/A
EPS (TTM) -0.0050
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
Fair Value

Subscribe to Premium to view Fair Value for MMJ.CN

Related Research

Matica Announces Sales Approval in Saskatchewan

Toronto, Ontario–(Newsfile Corp. – November 2, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that Matica subsidiary RoyalMax Biotechnology Canada Inc. (“RoyalMax”) has received approval to supply cannabis from the Saskatchewan Liquor and Gaming Authority (SLGA), the provincial regulator responsible for permitting and monitoring the operation of local cannabis wholesalers and retailers in the Province. As a newly registered supplier for the Province .

Preparing for 75 percent renewables

A major refurbishment of the Moyle Interconnector in Northern Ireland brings new opportunities for owner-operator Mutual Energy.

Matica’s Subsidiary, RoyalMax, Announces Start of Commercial Activity with Receipt of Sales Licence

Toronto, Ontario–(Newsfile Corp. – September 8, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that its subsidiary, RoyalMax Biotechnology Canada Inc. (“RoyalMax”), has received approval from Health Canada for its amended Sales Licence (the “Sales Licence”). The Sales Licence permits for the sale of cannabis products to all authorized provincial and territorial distributors/retailers and registered medical patients through out all of .

Matica Announces RoyalMax Licensing Update

Toronto, Ontario–(Newsfile Corp. – August 14, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that its subsidiary, RoyalMax Biotechnology Canada Inc. (“RoyalMax”), has been informed by Health Canada that its application to amend the licences to add sales of dried cannabis has been advanced from the paper review stage. This is an important step forward for Matica and RoyalMax as the application has been advanced .

Matica Welcomes Former Canadian National Soccer Team Forward, Ali Gerba, to the Board of Directors

Toronto, Ontario–(Newsfile Corp. – July 2, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to welcome Mr. Ali Gerba to the board of directors of the Company, subject to regulatory approval. Mr. Gerba brings extensive experience in Quebec’s business environment, as well as a strong connection with the world of professional sports. Mr. Gerba has a strong interest in how Medical Cannabis products have begun .

Matica Announces Delayed Filing of Interim Financial Statements Pursuant to OSC Blanket Instrument 51-502

Toronto, Ontario–(Newsfile Corp. – May 22, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) today announced that it will be delaying the filing and delivery of certain of its continuous disclosure documents, in accordance with Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements of the Ontario Securities Commission (the “Blanket Exemption Order”) which was adopted for the purpose of providing certain filing and other relief .

RoyalMax Biotechnology Canada Inc. Signs Cannabis Genetics Supply Agreement with Franchise Cannabis Corp’s Wholly Owned Danish Subsidiary Rangers Pharmaceuticals A/S for the Supply of New, Award Winning Cannabis Genetics

Toronto, Ontario–(Newsfile Corp. – May 7, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”), is pleased to announce its subsidiary, RoyalMax Biotechnology Canada Inc. (“RoyalMax”), has entered into a Purchase Agreement (the “Purchase Agreement”) with Franchise Cannabis Corp.’s (“Franchise”) wholly owned subsidiary, Rangers Pharmaceuticals A/S (“Rangers”), to acquire cannabis genetics from the first legally registered seedbank in Europe. Under the Purchase Agreement, RoyalMax will acquire high THC .

Matica Announces Delayed Filing of Annual Disclosure Documents Pursuant to OSC Blanket Instrument 51-502

The Company is relying on the Blanket Exemption Order in delaying (i) the filing of its annual consolidated financial statements and related management discussion and analysis for the year ended December 31, 2019 (collectively, the “Required Annual Filings”), (ii) compliance with the delivery requirements of applicable securities laws relating to the Required Annual Filings, and (iii) the filing of the business acquisition report with regard to the closing of the Company’s acquisition of a 70% equity interest in RoyalMax Biotechnology Canada Inc. The officers and directors of the Company and certain other persons will remain subject to a trading black-out pursuant to which such persons are prohibited from trading in any securities of the Company until the end of the second full trading day following the day on which the Required Annual Filings are filed on SEDAR and a corresponding news release is issued by the Company.

Matica Enterprises, Inc. Discusses Upcoming Revenue Potential with The Stock Day Podcast

Phoenix, Arizona–(Newsfile Corp. – March 12, 2020) – The Stock Day Podcast welcomed Matica Enterprises, Inc. (OTCQB: MMJFF) (“the Company”), a multi-faceted, innovative company in the Quebec cannabis space. CEO of the Company, Boris Ziger, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on the medical sales license that was recently secured by the Company’s subsidiary, RoyalMax. “That’s a huge development for us. This has really been what we’ve been .

Matica Subsidiary Receives Sales Licence

The standard processing licence will allow RoyalMax to deliver products to the recreational market throughout Canada. With the medical sales licence RoyalMax, will be able to provide product directly to appropriately documented patients who use cannabis for medical purposes. RoyalMax will immediately initiate its marketing and distribution program to bring high quality Quebec grown cannabis to store shelves.

Matica’s Interest in RoyalMax Released

On April 6th, 2017 the Company signed a definitive agreement (“the agreement”) allowing for Matica to become a majority owner (70%) of RoyalMax, at the time a late stage applicant under the then Access to Cannabis for Medical Purposes Regulation (“ACMPR”). As per the agreement, Matica could earn a 70% interest in RoyalMax by supplying funding and resources to build out the production facility in Dorval, Quebec. To earn a 70% interest in RoyalMax, Matica has issued 6,000,000 common shares in Company stock and has paid $735,000 with a further $250,000 due in the second quarter of this year, and has financed the retro-fitting and licensing of the Dorval facility.

Matica Welcomes Roop Mundi To The Board

As a former securities lawyer and retailer of CBD products in his own right, Mr. Mundi brings a unique skill set to the board of Matica. Mr. Roop Mundi currently serves as Chief Executive Officer of Infuzed Brands Inc. Infuzed is a beverage company that focuses on CBD infused beverages. In addition, Mr. Mundi owns and operates Mundi Capital Ventures – a private equity firm focused on consumer products distribution and logistics.

Construction Permits Received for Hemmingford Greenhouse Project

Construction of the planned 200,000 square foot greenhouse project is set to begin immediately. As with the Dorval facility, at Hemmingford, we will be growing the kind of high quality product that consumers are demanding. Matica is a multi-faceted, innovative company in the Quebec cannabis space.

Find the latest MaticaEnterpr (MMJ.CN) stock quote, history, news and other vital information to help you with your stock trading and investing. ]]>